Simple vaccine timing could save thousands of newborns
NCT ID NCT04658680
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving the BCG vaccine (normally given for tuberculosis) at the very first health visit after birth can lower the chance of death in the first 42 days of life. Over 22,000 infants in rural Guinea-Bissau are taking part. Some health centers will offer BCG every day, while others stick to the usual weekly schedule. The goal is to see if earlier vaccination reduces deaths by 25%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCG vaccine (live attenuated Mycobacterium bovis)
- What this could lead to
- If it works, this simple change in vaccine timing could prevent many infant deaths in high-risk areas.
- What could go wrong
- This is a single trial in rural Guinea-Bissau; results may not apply elsewhere. The 25% reduction is a hypothesis, not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bandim Health Project
Bissau, Guinea-Bissau
More trials for these conditions
Other studies related to the condition(s) this trial covers.